Sermorelin Acetate
Sermorelin is a synthetic 29-amino-acid analog of growth-hormone-releasing hormone (GHRH) studied in growth-hormone axis research.
We have not published an audit on Sermorelin Acetate. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
Sermorelin is a small peptide that copies the first 29 amino acids of the body's natural growth hormone-releasing hormone (GHRH). It fits the pituitary gland's GHRH receptor, triggering a normal growth hormone (GH) pulse. [Source: Peptide Dosing Protocols]
Sermorelin is a short copy of the brain signal that tells the pituitary gland to release growth hormone, and because it works through the body's own system, the body's natural safety brake (somatostatin) stays active to prevent growth hormone from going too high.
Reported side effects
The most common side effect is mild pain, swelling, or redness at the injection site (seen in about 17% of trial participants), while less common effects like headache, flushing, dizziness, and nausea each occurred in under 1% of patients.
Who should avoid it
People who are pregnant or breastfeeding, have active cancer, a known allergy to sermorelin, untreated hypothyroidism, are on glucocorticoids, or have GH deficiency caused by a brain lesion should generally avoid sermorelin, and anyone using it should do so under the supervision of a licensed clinician.
What gets monitored
Baseline IGF-1, full thyroid panel, fasting glucose, and comprehensive metabolic panel; follow-up thyroid labs standard due to hypothyroidism risk. [Source: Peptide Dosing Protocols]
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Sermorelin Acetate or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Standard: 200-300 mcg · Low: 100 mcg · High: 400-500 mcg | nightly3-6 months · Cycle length Planning note 4 weeks 1 vial 28 nights of 200 mcg from one vial. | subcutaneous injection | Peptide Dosing ProtocolsWhat it saysHide(secondary reference; provider confirmation required). Half-life: 11-12 minutes. Common dose is 200-300 mcg subQ nightly. |
| 200-300 mcg | Once daily at bedtime, 5 nights per week3-6 months | subcutaneous or oral | Peptide Protocol WikiWhat it saysHide(secondary reference; provider confirmation required). |
- nightly3-6 months · Cycle length Planning note 4 weeks 1 vial 28 nights of 200 mcg from one vial.
- subcutaneous injection
- Peptide Dosing Protocols
What it saysHide
(secondary reference; provider confirmation required). Half-life: 11-12 minutes. Common dose is 200-300 mcg subQ nightly.
- Once daily at bedtime, 5 nights per week3-6 months
- subcutaneous or oral
- Peptide Protocol Wiki
What it saysHide
(secondary reference; provider confirmation required).
- 3 mL bacteriostatic (BAC) water in a 10 mg vial gives 3 units per 100 mcg on a U-100 insulin syringe.
- Bacteriostatic water
Common questions
What is the starting dose of sermorelin?
Common adult research-context starting guidance is 100-200 mcg subQ at bedtime for the first 1-2 weeks, then titrating to 200-300 mcg nightly.
How much BAC water do you use to reconstitute a 10 mg sermorelin vial?
A common research-context setup is 3 mL of bacteriostatic water in a 10 mg vial.
Check 10 mg in 3 mL in the calculator →How many units of sermorelin should I inject?
It depends on your vial size and how much BAC water you used.
What is sermorelin's half-life?
Sermorelin's plasma half-life is approximately 11-12 minutes after either IV or subQ injection.
Is sermorelin FDA-approved in 2026?
Sermorelin was FDA-approved in 1990 and 1997, but there is no currently marketed FDA-approved product as of June 2026.
Is sermorelin legal to compound in 2026?
Yes, sermorelin remains in FDA 503A Category 1, allowing licensed compounding pharmacies to prepare it.
What are the most common side effects of sermorelin?
The most common side effect was a mild injection-site reaction in about 1 in 6 participants.
What results can be expected from sermorelin?
Sleep and recovery changes often appear in 2-4 weeks, while body-composition shifts usually need 3-6 months.
Sources
- 01Ishida J, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications (2020)
- 02Walker RF. Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging (2006)
- 03Cunha JP. Sermorelin Acetate prescribing information. RxList (FDA-era label content, rev. 10/2/2001) (2022)
- 04U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (503A Category 1 / Category 2 list). FDA.gov (2026)
- 05U.S. Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (503A Bulks List review). FDA.gov advisory committee calendar (2026)
- 06Mayo Clinic. Sermorelin (injection route) - side effects and dosage. Mayo Clinic Drugs & Supplements (2025)
- 07DrugBank. Sermorelin (DB00010) drug profile. DrugBank Online (2026)
- 08PubChem. Sermorelin (CID 16132413). PubChem (NCBI) (2026)
- 09Merriam GR, et al. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatrica Supplement (1993)
- 10Frier Levitt Attorneys at Law. Regulatory Status of Peptide Compounding in 2025 (sermorelin and NAD+ as Category 1 examples). Frier Levitt (2026)
- 11ScienceDirect Topics. Sermorelin summary and references. ScienceDirect (Elsevier) (2025)
The reference sections above are imported from our compound knowledge base, which classes the evidence for Sermorelin Acetate as emerging. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.
Blend of Tesamorelin (GHRH analog) and Ipamorelin (GHRP), studied for GH-axis support, visceral fat, and recovery.
Glutathione is a tripeptide antioxidant central to cellular redox biology research.
Blend of retatrutide (triple incretin agonist) and MOTS-c (mitochondrial-derived peptide), studied for metabolic and body-composition research.
Semaglutide is one of the most widely studied weight-loss and diabetes drugs in the world.
5-Amino-1MQ is a small molecule studied for its potential to help the body shrink fat cells and raise NAD+ levels without cutting appetite.
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. Studied in tissue-repair and regeneration research models.